文章名稱引用次數(shù)

• Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology120
• The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology94
• Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology80
• Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology76
• A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)55
• Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations53
• Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum46
• Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial45
• Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction44
• Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology43